December 8, 2009 - CNN Money
SAN DIEGO, Dec. 8, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB), announced today that Health Canada has issued a Medical Device License for the TearLab Osmolarity System. TearLab is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED), in conjunction with other methods of clinical evaluation. The Health Canada license allows the company to immediately begin marketing the system in Canada.
"TearLab represents an excellent solution for practitioners and patients alike, as it offers a rapid and very easy to undertake screening for tear osmolality values in the practice, with no discomfort to the patient," stated optometrist and researcher, Lyndon Jones PhD. Dr. Jones is a professor at the University of Waterloo's School of Optometry and Associate Director of the Centre for Contact Lens Research and has used the TearLab device in a variety of studies for several months.
Elias Vamvakas, Chairman and Chief Executive Officer of TearLab Corporation said, "This Health Canada approval is another significant regulatory and commercialization milestone for our Company. In many respects, Canadian optometrists and ophthalmologists have been at the forefront of eye care innovation. Accordingly, we are confident that they will quickly adopt TearLab as an adjunct to their practices."
No comments:
Post a Comment